Humacyte, Inc. (HUMA) Form 8-K — Sep 28, 2026
Humacyte (Nasdaq: HUMA) appointed Scott Coward and Paul Kuznik to its Board of Directors on September 22, 2026, expanding board expertise in commercialization and life sciences. Coward is a former Exact Sciences EVP and Chief Legal Officer with public company board and M&A integration experience, and joins the Audit Committee. Kuznik is a vascular and cardiovascular medtech executive who led Bolton Medical and Terumo Aortic North America, and joins the Commercial Committee. The appointments come as Humacyte scales the Symvess launch and prepares for a planned U.S.
Key figures
- Committee fee per annum
- $5,000
- Director option grant shares
- 125000
- Director annual cash retainer
- $50,000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.